Literature DB >> 23192379

Neuroendocrine-derived peptides promote prostate cancer cell survival through activation of IGF-1R signaling.

John O DaSilva1, George P Amorino, Eli V Casarez, Bradley Pemberton, Sarah J Parsons.   

Abstract

BACKGROUND: Neuroendocrine (NE) cells promote the progression of prostate cancer to a castration-resistant state through the production of paracrine growth factors. We have demonstrated this principle using in vitro and in vivo proliferative endpoints; however, the contributions of NE-derived pro-survival factors and anti-apoptosis to this phenomenon have not been thoroughly investigated.
METHODS: Here, we utilized conditioned-medium (CM) from LNCaP cells, engineered to undergo NE differentiation, and examined its effects on PC3 and LNCaP cell survival.
RESULTS: Statistically significant changes in clonogenic survival, Annexin V staining, PARP cleavage and trypan blue positivity of approximately twofold were observed in the presence of NE-derived CM relative to control-CM for both LNCaP and PC3 cells. These changes were partially abrogated by antagonists of the neuropeptides neurotensin, bombesin, and PTHrP. Selective inhibitors of IGF-1R, EGFR or Src caused significant and nearly complete blockade of prostate cancer cell survival due to NE secretions. Similar increases in cell survival were observed for LNCaP or PC3 cells treated with NE-derived medium in the presence of docetaxel. Increased phosphorylation of IGF-1R, following treatment with NE-derived medium, was accompanied by decreased protein tyrosine phosphatase, receptor type F (PTPRF) mRNA, and protein levels. Overexpression of PTPRF decreased cell survival, the amplitude and duration of IGF-1R phosphorylation, and enhanced PARP cleavage in the presence of NE-derived medium.
CONCLUSIONS: These data support the hypothesis that NE-derived factors act upon prostate cancer cells to stimulate pro-survival signaling and describe a novel mechanism of cross-talk between NE-derived factors and IGF-1R, mediated in part by PTPRF.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23192379      PMCID: PMC4085781          DOI: 10.1002/pros.22624

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  51 in total

1.  Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment.

Authors:  T Jiborn; A Bjartell; P A Abrahamsson
Journal:  Urology       Date:  1998-04       Impact factor: 2.649

2.  Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect.

Authors:  K Reiss; C D'Ambrosio; X Tu; C Tu; R Baserga
Journal:  Clin Cancer Res       Date:  1998-11       Impact factor: 12.531

3.  Distinct functions of the two protein tyrosine phosphatase domains of LAR (leukocyte common antigen-related) on tyrosine dephosphorylation of insulin receptor.

Authors:  K Tsujikawa; N Kawakami; Y Uchino; T Ichijo; T Furukawa; H Saito; H Yamamoto
Journal:  Mol Endocrinol       Date:  2001-02

4.  Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase.

Authors:  L F Lee; J Guan; Y Qiu; H J Kung
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

5.  Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor.

Authors:  G O Hellawell; D J P Ferguson; S F Brewster; V M Macaulay
Journal:  BJU Int       Date:  2003-02       Impact factor: 5.588

6.  Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.

Authors:  June M Chan; Meir J Stampfer; Jing Ma; Peter Gann; J Michael Gaziano; Michael Pollak; Edward Giovannucci
Journal:  J Natl Cancer Inst       Date:  2002-07-17       Impact factor: 13.506

7.  GABAB receptor activation protects neurons from apoptosis via IGF-1 receptor transactivation.

Authors:  Haijun Tu; Chanjuan Xu; Wenhua Zhang; Qiuyao Liu; Philippe Rondard; Jean-Philippe Pin; Jianfeng Liu
Journal:  J Neurosci       Date:  2010-01-13       Impact factor: 6.167

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

9.  NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.

Authors:  Ren Jie Jin; Yongqing Wang; Naoya Masumori; Kenichiro Ishii; Taiji Tsukamoto; Scott B Shappell; Simon W Hayward; Susan Kasper; Robert J Matusik
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

Review 10.  Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.

Authors:  C J Marshall
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

View more
  16 in total

1.  Neuroendocrine differentiation of prostate cancer.

Authors:  Zhen Li; Clark J Chen; Jason K Wang; Elaine Hsia; Wei Li; Jill Squires; Yin Sun; Jiaoti Huang
Journal:  Asian J Androl       Date:  2013-03-18       Impact factor: 3.285

2.  Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.

Authors:  Qiang Dang; Lei Li; Hongjun Xie; Dalin He; Jiaqi Chen; Wenbing Song; Luke S Chang; Hong-Chiang Chang; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Oncol       Date:  2015-03-05       Impact factor: 6.603

3.  Elevating SOX2 in prostate tumor cells upregulates expression of neuroendocrine genes, but does not reduce the inhibitory effects of enzalutamide.

Authors:  Ethan P Metz; Phillip J Wilder; Jixin Dong; Kaustubh Datta; Angie Rizzino
Journal:  J Cell Physiol       Date:  2019-10-06       Impact factor: 6.384

4.  [Infiltrating mast cells promote neuroendocrine differentiation and increase docetaxel resistance of prostate cancer cells by up-regulating p21].

Authors:  Yi-Hong Ou; Yao-Dong Jiang; Qi Li; Yong-Jiang Zhuang; Qiang Dang; Wan-Long Tan
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-06-20

Review 5.  [Neuroendocrine prostate cancer].

Authors:  A Kretschmer; C Wittekind; C G Stief; C Gratzke
Journal:  Urologe A       Date:  2015-12       Impact factor: 0.639

6.  Obesity-related gut hormones and cancer: novel insight into the pathophysiology.

Authors:  Maria Angela Guzzardi; Gabriella Pugliese; Filomena Bottiglieri; Caterina Pelosini; Giovanna Muscogiuri; Luigi Barrea; Silvia Savastano; Annamaria Colao
Journal:  Int J Obes (Lond)       Date:  2021-06-04       Impact factor: 5.095

Review 7.  Receptor-type protein tyrosine phosphatases in cancer.

Authors:  Yu Du; Jennifer R Grandis
Journal:  Chin J Cancer       Date:  2014-10-17

Review 8.  SRC: marker or actor in prostate cancer aggressiveness.

Authors:  Virginie Vlaeminck-Guillem; Germain Gillet; Ruth Rimokh
Journal:  Front Oncol       Date:  2014-08-18       Impact factor: 6.244

9.  LncRNA TCONS_00004099-derived microRNA regulates oncogenesis through PTPRF in gliomas.

Authors:  Yuhao Wang; Aijun Shan; Zhiwei Zhou; Wenpeng Li; Lin Xie; Bo Du; Bingxi Lei
Journal:  Ann Transl Med       Date:  2021-06

10.  REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer.

Authors:  Charlotte Svensson; Jens Ceder; Diego Iglesias-Gato; Yin-Choy Chuan; See Tong Pang; Anders Bjartell; Roxana Merino Martinez; Laura Bott; Leszek Helczynski; David Ulmert; Yuzhuo Wang; Yuanjie Niu; Colin Collins; Amilcar Flores-Morales
Journal:  Nucleic Acids Res       Date:  2013-10-24       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.